Sustained Or Differential Release Patents (Class 424/457)
-
Publication number: 20150104505Abstract: Pharmaceutical compositions in unit dose form comprising a hard or soft capsule containing a fill consisting of one or more inert ingredients, and one or more coatings on the capsule, wherein at least one coating comprises at least one active pharmaceutical ingredient.Type: ApplicationFiled: September 30, 2014Publication date: April 16, 2015Inventors: Manish S. SHAH, Ray J. DiFalco
-
Patent number: 9005943Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.Type: GrantFiled: October 2, 2007Date of Patent: April 14, 2015Assignee: The Invention Science Fund I, LLCInventors: Ed Harlow, Roderick A. Hyde, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
-
Publication number: 20150071998Abstract: An abuse resistant oral pharmaceutical composition, comprising: a barrier layer, comprising a first polymer; a diffusion layer, comprising a second polymer, substantially covering the barrier layer, wherein the diffusion layer is bonded to the barrier layer and comprises a drug that is substantially homogeneously distributed within the second polymer and diffuses from the diffusion layer within the gastrointestinal (GI) tract; and optionally an expansion layer comprising an expandable polymer, wherein the expansion layer is substantially covered by the barrier layer. Methods of making the same and methods of using the same are also provided.Type: ApplicationFiled: November 7, 2014Publication date: March 12, 2015Inventors: Manish S. Shah, Ray J. DiFalco
-
Publication number: 20150071997Abstract: Methods of encapsulating cargo in a microgel droplet, microgel droplets prepared according the provided methods, and methods of use thereof are disclosed. The methods of preparing cargo-encapsulated microgels generally include flowing through a flow-focusing nozzle of a microfluidic device a macromer phase, an oil phase, and a crosslinker phase to form microgel droplets by oil-water emulsion. The phases are pumped, injected, or flowed through the microfluidic device such that as the macromer phase approaches the flow focusing nozzle, the co-flowing oil phase shields the macromer from contact with the crosslinker phase until flow instability occurs and macromer phase droplets form. After flow instability occurs, the crosslinker diffuses from the crosslinker phase into the droplets in an effective amount to covalently crosslink the macromer into a microgel network encapsulating the cargo in the crosslinked macromer.Type: ApplicationFiled: September 9, 2014Publication date: March 12, 2015Inventors: Andres Garcia, Devon Headen, Edward A. Phelps, Guillaume A. Aubry, Hang Lu, Cristina Gonzalez Garcia
-
Patent number: 8975273Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: GrantFiled: September 11, 2014Date of Patent: March 10, 2015Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Patent number: 8975271Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: GrantFiled: December 3, 2013Date of Patent: March 10, 2015Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Patent number: 8969369Abstract: Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid.Type: GrantFiled: December 20, 2013Date of Patent: March 3, 2015Assignee: Purdue Pharma L.P.Inventors: Frank S. Caruso, Huai-Hung Kao
-
Patent number: 8962017Abstract: A high-efficacy, long-acting formulation of silymarin, comprising silymarin solid dispersion, silymarin-loaded silica nanoparticles, slow-release matrix material and release enhancer, wherein the mass ratio of these components is silymarin solid dispersion:silymarin-loaded silica nanoparticles:slow-release matrix material:release enhancer=1:0.5˜1.25:0.1˜0.3:0.1˜0.3; the drug loading rate of the said silymarin-loaded silica nanoparticles is 51.95%-52.87%; the said silymarin solid dispersion contains povidone K30, soybean lecithin and acrylic resin IV, and the mass ratio between silymarin and other medical accessories in silymarin solid dispersion is silymarin:povidone K30:soybean lecithin:acrylic resin IV=1:1˜3:0.3˜0.8:0.2˜0.5. Compared with the existing formulations, the half life of the high-efficacy, long-acting formulation of silymarin disclosed in this invention is 2.3 times longer while the mean residence time (MRT) of which is 9.Type: GrantFiled: November 23, 2009Date of Patent: February 24, 2015Assignee: Jiangsu UniversityInventors: Ximing Xu, Jiangnan Yu, Shanshan Tong, Yuan Zhu, Xia Cao
-
Publication number: 20150050335Abstract: The present disclosure relates to methods for making extended-release formulations of water-soluble active pharmaceutical ingredients such as metformin HCl. In one aspect, the disclosure provides a method that includes adding an aqueous solution of an active pharmaceutical ingredient to an agitated mixture of one or more release-modifying polymers and optionally one or more binders in one or more organic solvents, the one or more organic solvents together being an antisolvent for the active pharmaceutical ingredient, water being sufficiently soluble in the one or more organic solvents such that the water added as part of the aqueous solution dissolves in the mixture, the addition thereby precipitating the active pharmaceutical ingredient; separating the active pharmaceutical ingredient and the one or more release-modifying polymers and, if present, the one or more binders from the one or more organic solvents to yield co-processed particles; and drying the co-processed particles.Type: ApplicationFiled: February 28, 2013Publication date: February 19, 2015Inventors: Deniz Erdemir, Shih-Ying Chang, Divyakant Desai, San Kiang
-
Publication number: 20150050334Abstract: The present invention relates to new acid resistant hard pharmaceutical capsules, a process for their manufacture and use of such capsules particularly but not exclusively for oral administration of pharmaceuticals, veterinary products, food and dietary supplements to humans or animals. The capsules of the invention are obtained by aqueous compositions comprising a water soluble film forming polymer and gellan gum in a mutual weight ratio of 4 to 15 weight parts of gellan gum for 100 weight parts of film forming polymer.Type: ApplicationFiled: August 27, 2014Publication date: February 19, 2015Inventors: Dominique Nicolas Cade, Xiongwei David He
-
Patent number: 8956647Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.Type: GrantFiled: July 26, 2013Date of Patent: February 17, 2015Assignee: Dr. Falk Pharma GmbHInventors: Norbert Otterbeck, Peter Gruber
-
Publication number: 20150044283Abstract: Single oral solid dosage form comprising an immediate release first dosage composition having at least two antibiotic agents and a delayed release second dosage composition having a proton pump inhibitor are provided herein. The single oral solid dosage form according to some aspects of the invention can be used for the treatment of disorders associated with infection by H. pylori or the prevention of recurrence of disorders associated with infection by H. pylori.Type: ApplicationFiled: October 24, 2014Publication date: February 12, 2015Inventors: Reza Fathi, Gilead Raday, Guy Goldberg, Patrick Gosselin
-
Publication number: 20150037405Abstract: The present invention relates to pharmaceutical compositions of levodopa and carbidopa. In particular, the invention relates to modified release pharmaceutical compositions of levodopa and carbidopa with at least one organic acidic excipient. The invention also relates to processes for the preparation of such compositions and use thereof for treatment of Parkinson's disease.Type: ApplicationFiled: August 4, 2014Publication date: February 5, 2015Inventors: Sushrut Krishnaji Kulkarni, Pavak Rajnikant Mehta, Sameer Sagar Kochar, Krishnakumar Vinubhai Patel
-
Patent number: 8945616Abstract: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, and an extended release polymer. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration.Type: GrantFiled: February 17, 2009Date of Patent: February 3, 2015Assignee: Mylan Pharmaceuticals Inc.Inventors: Mummini Aruna Murty, Boyong Li
-
Patent number: 8945615Abstract: Embodiments of a controlled release minitablet comprise an extended release core and an optional pH dependent delayed release coating thereon, wherein the extended release core comprises budesonide, a carrier, an extended release polymer, and an acid. The budesonide may be embedded in the extended release polymer to facilitate extended release of the budesonide upon administration.Type: GrantFiled: February 17, 2009Date of Patent: February 3, 2015Assignee: Mylan Pharmaceuticals Inc.Inventors: Mummini Aruna Murty, Boyong Li
-
Publication number: 20150030675Abstract: The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.Type: ApplicationFiled: April 25, 2014Publication date: January 29, 2015Applicant: Valeant International BermudaInventors: Fang ZHOU, Paul MAES
-
Patent number: 8940328Abstract: An orally administrable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.Type: GrantFiled: March 8, 2013Date of Patent: January 27, 2015Assignee: Dr. Falk Pharma GmbHInventors: Norbert Otterbeck, Peter Gruber
-
Publication number: 20150024043Abstract: Medi-Cap a specialized absorbable capsule of various shapes and sizes. It may come prefilled with desired medication or material or it can come in a two-piece snap together capsule that can be filled with desired medication/material by the medical professional. (Most Likely prefilled) Medi-Cap will be time released meaning that each capsule used in an area of treatment will have a specific time in which the capsule will degrade and release the medication in the area of operation or treatment. Depending on what Medi-Cap will be used for there should be different capsules with different absorbing times.Type: ApplicationFiled: July 18, 2013Publication date: January 22, 2015Inventor: Sachin Patel
-
Patent number: 8932618Abstract: The present disclosure relates to a drug delivery device including a biodegradable housing and a hydrogel within the biodegradable housing. The housing, the hydrogel, or both, may include a bioactive agent. Also disclosed is a method of drug delivery including the steps of forming the biodegradable housing, in embodiments a hydrogel, suspending a bioactive agent in the hydrogel, and introducing a second hydrogel and/or precursors of a second hydrogel into the biodegradable housing.Type: GrantFiled: July 11, 2013Date of Patent: January 13, 2015Assignee: Confluent Surgical, Inc.Inventors: Phillip D. Blaskovich, Rachit Ohri, Steven L. Bennett
-
Publication number: 20150010624Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: July 2, 2014Publication date: January 8, 2015Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Patent number: 8911778Abstract: An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.Type: GrantFiled: August 3, 2012Date of Patent: December 16, 2014Assignee: Dr. Falk Pharma GmbHInventors: Norbert Otterbeck, Peter Gruber
-
Publication number: 20140363504Abstract: An absorbable encapsulated calcium in hypromellose capsule, characterized in that the encapsulated calcium comprises calcium amino acid chelate extracted from soya bean, aspartate, calcium amino acid chelate which is obtained from chelation of aspartate with calcium hydroxide, collagen, lecithin, soya bean extract, lactose, calcium carbonate, in the ratio of 4:8:8:10:8:12:10:40 being capsulated into hypromellose capsule capable of being absorbed in vivo at the small intestine beyond the stomach, which maximize human absorption of calcium.Type: ApplicationFiled: April 18, 2014Publication date: December 11, 2014Applicant: The Beauty Nation Ptd LtdInventor: Tan See LENG
-
Patent number: 8906687Abstract: Bone cages are disclosed including devices for biocompatible implantation. The structures of bone are useful for providing living cells and tissues as well as biologically active molecules to subjects.Type: GrantFiled: June 12, 2006Date of Patent: December 9, 2014Assignee: The Invention Science Fund I, LLCInventors: Ed Harlow, Roderick A. Hyde, Edward K. Y. Jung, Robert Langer, Eric C. Leuthardt, Lowell L. Wood, Jr.
-
Patent number: 8901128Abstract: A novel controlled release pharmaceutical dosage form comprising a therapeutically effective amount of ranolazine or pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), enantiomer(s) thereof, one or more lipid(s) as release controlling agent(s) and one or more pharmaceutically acceptable excipient(s).Type: GrantFiled: May 26, 2010Date of Patent: December 2, 2014Assignee: Lupin LimitedInventors: Ketan Bhasale, Raghavendra Naik, Subhasis Das, Vijaya Kumar Thommandru
-
Patent number: 8895065Abstract: There is provided a single unit oral dose pharmaceutical composition comprising a) levodopa or salts thereof from about 50 mg to about 300 mg in extended release form, b) carbidopa or salts thereof from about 10 mg to about 100 mg in extended release and c) entacapone or salts thereof from about 100 mg to about 1000 mg in immediate release form, optionally with other pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.Type: GrantFiled: May 29, 2012Date of Patent: November 25, 2014Assignee: Wockhardt Ltd.Inventors: Yatendra Kumar Gupta, Girish Kumar Jain, Munish Talwar, Manoj Mashalkar
-
Patent number: 8889190Abstract: An extended-release topiramate capsule that includes a capsule shell containing a single population of coated particles; wherein each coated particle includes a core and a coating thereon; wherein each particle core includes a homogeneous mixture comprising topiramate throughout its core; and wherein the coating includes one or more release controlling agent(s).Type: GrantFiled: January 17, 2014Date of Patent: November 18, 2014Assignee: Upsher-Smith Laboratories, Inc.Inventors: Sarah Michelle Betterman, Jaidev Srinivas Tantry, Laura Marie Patrick
-
Publication number: 20140335173Abstract: The present invention relates to novel release capsules, particularly for protecting moisture-sensitive materials, particularly compositions for production of chlorine dioxide. The invention also relates to methods of manufacture of such release capsules, uses of such release capsules, and products comprising them.Type: ApplicationFiled: November 27, 2012Publication date: November 13, 2014Inventors: Robert Wengeler, Jing Dreher, Andrew Patrick Full
-
Publication number: 20140322315Abstract: Provided herein are methods and compositions for treating ischemia or a disease or disorder that causes ischemia comprising contacting a subject with cysteamine, a cysteamine derivative, cystamine or a cystamine derivative. The disclosure also provides methods of modulating adiponectin levels in a subject comprising contact a subject with cysteamine, a cysteamine derivative, cystamine or a cystamine derivative.Type: ApplicationFiled: November 21, 2012Publication date: October 30, 2014Applicant: The Regents of the University of CaliforniaInventors: Ranjan Dohil, Susan A. Phillips
-
Patent number: 8871235Abstract: The present invention is directed to implantable compositions comprising substantially spherical bioactive glass particles.Type: GrantFiled: October 24, 2012Date of Patent: October 28, 2014Assignee: Synergy Biomedical LLCInventor: Mark D. Borden
-
Patent number: 8871275Abstract: The present invention deals with extended release pharmaceutical compositions comprising tolterodine, wherein the composition comprises: a) a drug layer comprising tolterodine tartrate, monosaccharide and/or disaccharide on an inert core; or a drug core comprising tolterodine tartrate, monosaccharide and/or disaccharide; and b) a polymer layer comprising extended release polymer(s). The invention also provides a process for the preparation of the above mentioned composition.Type: GrantFiled: August 6, 2008Date of Patent: October 28, 2014Assignee: Inventia Healthcare Private LimitedInventors: Sunil Beharilal Jaiswal, Ankur Janak Shah
-
Publication number: 20140314842Abstract: A gastroretentive drug formulation for the sustained release of an active agent in the gastrointestinal tract comprises an internal layer or compartment comprising an active agent and one or more pharmaceutical excipients, of which at least one is a polymer and two membranes forming together an envelope around the inner membrane, each membrane comprising at least one polymeric combination of an enteric polymer which is not soluble in gastric juice, and an hydrophilic swelling polymer, and at least one plasticizer.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: Nadav Navon, Eytan Moor, David Kirmayer, Elena Kluev, Giora Carni
-
Publication number: 20140314841Abstract: The present disclosure is directed to methods for inhibiting or suppressing metastasis of a tumor in a mammalian subject using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. Also described herein is a method for treating pancreatic cancer in a mammalian subject by administering a cysteamine product described herein.Type: ApplicationFiled: April 18, 2014Publication date: October 23, 2014Applicant: The United States of America, as Represented by the Secretary, Department of Health and Human ServInventors: Raj K. Puri, Bharat H. Joshi, Benjamin Rubin
-
Patent number: 8865210Abstract: Stable formulations of imidazolylalkyl-pyridines, including controlled-release formulations.Type: GrantFiled: February 13, 2007Date of Patent: October 21, 2014Assignee: Vanda Pharmaceuticals, Inc.Inventors: Christian N. Lavedan, Deepak Phadke
-
Publication number: 20140308346Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: ApplicationFiled: June 27, 2014Publication date: October 16, 2014Inventor: Thomas NAJARIAN
-
Patent number: 8858991Abstract: Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.Type: GrantFiled: January 19, 2012Date of Patent: October 14, 2014Assignee: Pathologica LLCInventors: John McKearn, Jeremy Blitzer
-
Publication number: 20140302134Abstract: The present invention relates to a formulation for the controlled release of active ingredients after the passage of the ileo-cecal-valve, comprising one or more active ingredients or one or more active ingredient containing cores (W), enveloped by one or more envelopments (C), which are dissoluble or permeable above an individual defined pH value and are dissoluble or permeable below another individual defined pH value, again enveloped by an envelopment (E), which is dissoluble or permeable above still another individual defined pH value.Type: ApplicationFiled: September 7, 2012Publication date: October 9, 2014Inventor: Roland Saur-Brosch
-
Publication number: 20140302136Abstract: A medicine delivery system delivers medicine such as a dietary supplement to improve prostate health and includes an outer capsule containing a saw palmetto extract and an inner capsule within the outer capsule and containing a carotenoid. The outer capsule is formed to dissolve in the stomach when ingested to release the saw palmetto extract into the stomach and the inner capsule is formed to pass into the duodenum to dissolve and release the carotenoid into the duodenum.Type: ApplicationFiled: March 27, 2014Publication date: October 9, 2014Applicant: U.S. NUTRACEUTICALS, LLC d/b/a Valensa InternationalInventors: John A. MINATELLI, W. Stephen HILL, Rudi E. MOERCK
-
Publication number: 20140288495Abstract: Timed release capsules administered in beverage preparations may be used for delayed release of flavor or color enhancements, and pharmaceuticals. A composite timed release capsule includes: a first layer, including a first material; a second layer, including a second material, such that the second material further includes inner bodies; and an inner layer, which includes a third material. A composite straw includes: a standard straw; a snap-off cap; an upper stop; a lower stop; timed release capsules, retained in position between the snap-off cap and the upper stop; composite timed release capsules, retained in position between the upper stop and the lower stop. A user can remove the snap-off cap to pour the timed release capsules into a drinking container, insert the composite straw into the drinking container, where the composite timed release capsules dissolve, and embedded inner bodies fall into the beverage.Type: ApplicationFiled: June 4, 2014Publication date: September 25, 2014Inventor: Alejandro I. Olmos
-
Patent number: 8840923Abstract: Slow-release excipients which comprise an association of at least one glycogen and at least one alginate with an alkaline-earth metal salt are useful for the preparation of slow-release pharmaceutical formulations.Type: GrantFiled: December 23, 2008Date of Patent: September 23, 2014Assignee: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla, Leonardo Marchitto, Lorella Ragni
-
Publication number: 20140271783Abstract: A combination of sheets can be combined into an ingestible unit. The individual sheets can be prepared to have one or more functionalities, such as providing a biologically active agent, disintegrating and opening the unit, controlling release of an agent, facilitating absorption from the GI tract, as well as many others. The individual sheets can be selectively identified for combining into a multifunctional ingestible unit with a random or predetermined arrangement or stacking pattern. The individual sheets can be loose in a capsule or laminated together into a stacked layered structure. The combination of sheets can be pressed, laminated, tableted, or otherwise prepared into an ingestible unit. The ingestible unit can be predetermined to be useful for administering a drug, drug combination, multi-drug regimen as well as tailored to subject-specific multi-drug therapeutic regimens. The sheets can be loaded with any type of agent ranging from drugs to anti-counterfeit agents.Type: ApplicationFiled: October 15, 2012Publication date: September 18, 2014Inventors: Rodolfo Pinal, Bo Zhou, Andrew Otte
-
Publication number: 20140271834Abstract: The present invention is directed to a pharmaceutical composition in unit dose form for orally delivering doxycycline to a human, the pharmaceutical composition comprising: a capsule, wherein the capsule is coated with a delayed release layer; wherein the delayed release layer comprises about 4 to 6 mg of doxycycline monohydrate and a binding agent, and wherein the delayed release layer is coated with an enteric coating; wherein the enteric coating dissolves at pH of about 5 to 6, and wherein the enteric coating is coated with an immediate release layer; wherein the immediate release layer comprises about 32 mg of doxycycline monohydrate and a binding agent, wherein the relative mean Cmax of the pharmaceutical composition is within 80.00% to 125.00% of a Cmax value of 510±220.7 ng/mL, after administration of a single dose of the pharmaceutical composition to humans in a fasting state; and wherein the relative mean AUC(0-?) of the pharmaceutical composition is within 80.00% to 125.Type: ApplicationFiled: October 16, 2013Publication date: September 18, 2014Applicants: Cerovene, Inc., Galderma S.A.Inventors: Jean-Pierre Etchegaray, Nathalie Wagner, Manish S. Shah, Ray J. Difalco
-
Publication number: 20140271842Abstract: The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.Type: ApplicationFiled: March 14, 2014Publication date: September 18, 2014Applicant: Pfizer Inc.Inventors: Scott Max Herbig, Sriram Krishnaswami, Joseph Kushner, IV, Manisha Lamba, Thomas C Stock
-
Publication number: 20140271840Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Patent number: 8821928Abstract: Layered pharmaceutical composition suitable for oral use in the treatment of diseases where absorption takes place over a large part of the gastrointestinal tract. The composition comprising A) a solid inner layer comprising i) an active substance, and ii) one or more disintegrants/exploding agents, one of more effervescent agents or a mixture thereof.Type: GrantFiled: June 4, 2008Date of Patent: September 2, 2014Assignee: Egalet Ltd.Inventors: Pernille Hoyrup Hemmingsen, Anders Vagno Pedersen, Daniel Bar-Shalom
-
Patent number: 8822423Abstract: We have disclosed affinity peptides toward infliximab. More specifically we have disclosed an affinity biomatrix where the affinity peptide is covalently attached to a biocompatible, biodegradable polymer. The affinity biomatrix is useful in preparing controlled release devices for infliximab.Type: GrantFiled: May 17, 2012Date of Patent: September 2, 2014Assignee: Janssen Biotech, Inc.Inventors: Daphne Ann Salick Ryan, John Kehoe, John Wheeler, Chunlin Yang, Abla Creasey
-
Patent number: 8809271Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: GrantFiled: June 29, 2012Date of Patent: August 19, 2014Assignee: Rani Therapeutics, LLCInventor: Mir Imran
-
Patent number: 8802636Abstract: The present invention features a novel therapy for effecting weight loss which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate derivative (e.g., topiramate) such that the subject experiences weight loss. The combination methods of the present invention also are effective against symptoms associated with Syndrome X. The invention also features pharmaceutical compositions and kits for use in the practice of these novel therapies.Type: GrantFiled: January 6, 2010Date of Patent: August 12, 2014Assignee: Vivus, Inc.Inventor: Thomas Najarian
-
Patent number: 8802139Abstract: An oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a first population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a first rate; a population of a basic substance; and a second population of a pharmaceutical active comprising a pharmaceutical active substance releasable at a second rate. In another embodiment, the oral pharmaceutical composition comprises multiple populations of at least one of beads, pellets, tablets and granules provided in a capsule, the composition comprising: a population of a pharmaceutical active; a population of a basic substance; a population of enteric coated pharmaceutical active; and a population of enteric coated basic substance. The composition can provide multiple site specific delivery of a pharmaceutical active in a rapid, delayed and/or sustained release manner into the plasma.Type: GrantFiled: June 3, 2004Date of Patent: August 12, 2014Assignee: Intellipharmaceutics Corp.Inventors: Isa Odidi, Amina Odidi
-
Patent number: 8796226Abstract: Long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer are provided. In particular, the long acting pharmaceutical composition comprises a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.Type: GrantFiled: August 19, 2010Date of Patent: August 5, 2014Assignee: Mapi Pharma Ltd.Inventors: Ehud Marom, Shai Rubnov
-
Publication number: 20140205662Abstract: The present invention is directed to a system and method for treating oral diseases in a subject. This method comprises the following steps; diagnosing the subject, and choosing one or a combination of medications, their dosing and desired time course and then delivering the medications to the desired site in the periodontal pocket by administering a plurality of microcapsules, capsules, the microcapsules comprising one or more pharmaceutical agent(s) that are released in a predetermined manner and in accordance with the pathophysiology of the targeted disease.Type: ApplicationFiled: November 3, 2011Publication date: July 24, 2014Applicant: The Research Foundation for The State University of New YorkInventors: Steven P. Engebretson, Nathan Blumberg, Lorne Golub